Clinical Trial Update: Nab-paclitaxel Plus Gemcitabine as First-line Therapy for Cisplatin-ineligible or Cisplatin-incurable Advanced Urothelial Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial of nab-paclitaxel plus gemcitabine as first-line therapy for cisplatin-ineligible or cisplatin-incurable advanced urothelial carcinoma has termina…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Transitional Cell Carcinoma
• Urothelial Carcinoma

Drugs mentioned

• Gemcitabine (Gemcitabine)
• Nab-paclitaxel (paclitaxel protein-bound)

Snippet

Sponsor: SCRI Development Innovations, LLC | Conditions: Urothelial Carcinoma, Bladder Cancer | Phase 2 | Status: TERMINATED | Results posted: 2022-01-13